Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (01349.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−10.2x

Market Cap

HKD 2.60B

MomentumView details →

1D Return

+0.20%

YTD Return

−9.89%

RSI (14)

47.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−10.2x

Market Cap

HKD 2.60B

RSI (14)

47.6

MomentumView details →

1D Return

+0.20%

YTD Return

−9.89%

ProfitabilityView details →

Gross Margin

87.34%

Net Margin

−18.66%

EBITDA Margin

−14.93%

ROE (TTM)

−5.77%

ROA (TTM)

−5.14%

Asset Turnover

0.28x

GrowthView details →

Revenue YoY

−3.82%

EPS YoY

—

FCF YoY

+491.24%

Revenue CAGR 3Y

−12.71%

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

HKD 0.03

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

6.53x

Quick Ratio

6.41x

Div Yield

—

Div Rate

—

Div Growth 1Y

−67.04%

Financials snapshotView financials →

Revenue (TTM)

664.95M

Net Income (TTM)

−124.10M

Op. CF (TTM)

166.02M

Next earningsOct 22, 2026 →

Latest newsMore news →

Fudan Zhangjiang Bio-Pharmaceutical reported interim results for the six months ended June 2026, with net profit of 36.895 million RMB, up 545% year-on-year.21d ago

Similar companies

Supernus Pharmaceuticals, Inc.SUPN HUTCHMED (China) LimitedHCM Bausch Health Companies Inc.BHC Hua Medicine (Shanghai) Ltd.02552.HK ST交昂600530.SH 圣达生物603079.SH Find similar companies →

Latest newsMore news →

Fudan Zhangjiang Bio-Pharmaceutical reported interim results for the six months ended June 2026, with net profit of 36.895 million RMB, up 545% year-on-year.21d ago